A traditional Chinese medicine composition for treating heart failure and insufficient heart function

Abstract

This invention discloses a traditional Chinese medicine composition for treating heart failure and insufficient cardiac function, belonging to the field of pet medicine technology. The composition, based on a 30 kg pet, is made from the following raw materials in parts by weight: ginseng 5-7g, astragalus 18-22g, salvia miltiorrhiza 8-12g, lepidium seed 4-6g, aconite root 1-3g, alisma 8-12g, poria cocos 8-12g, polygonatum odoratum 4-6g, cinnamon twig 2-4g, chuanxiong rhizome 1-3g, coptis chinensis root 1-3g, and licorice root 2-4g. This composition follows the principles of invigorating qi and warming yang, promoting blood circulation and removing blood stasis, and promoting diuresis and reducing swelling. It can effectively improve heart failure, insufficient cardiac function, and insufficient cardiac output in pets, increase left ventricular ejection fraction and cardiac output, and reduce myocardial damage indicators. It has definite clinical efficacy, high safety, and few toxic side effects, is suitable for the physiological characteristics of dogs, cats, and other pets, and has a simple preparation process, making it suitable for widespread clinical application in pets.

Description

Technical Field

[0001] This invention relates to the field of pet medicine, and in particular to a traditional Chinese medicine composition for treating heart failure and insufficient cardiac function. Background Technology

[0002] With the increase in pet ownership, pets are aging, becoming obese, and developing cardiovascular diseases. Heart failure in pets has become one of the most common serious illnesses in clinical practice. Its core pathological features are insufficient cardiac function and reduced cardiac output, which cannot meet the normal metabolic needs of the pet's body. Clinical manifestations include difficulty breathing, weakness, edema, lethargy, and decreased exercise tolerance. In severe cases, it can lead to the death of the pet.

[0003] Currently, the clinical treatment of heart failure in pets mostly uses Western medicine, such as cardiac glycosides, angiotensin-converting enzyme inhibitors (ACEIs), and diuretics. Although these can quickly relieve symptoms, long-term use can easily lead to drug resistance and has certain toxic side effects, such as gastrointestinal reactions and liver and kidney damage, which puts an extra burden on the pet's body.

[0004] Traditional Chinese medicine (TCM) has advantages such as syndrome differentiation and treatment, addressing both the root cause and symptoms, minimal side effects, and low likelihood of drug resistance, leading to its increasing application in the treatment of pet diseases. In TCM, pet heart failure falls under the categories of "cough and asthma," "edema," and "phlegm retention." Its pathogenesis involves insufficient heart qi and yang, blood stasis, internal retention of dampness, and dysfunction of the internal organs, resulting in weak myocardial contraction and insufficient cardiac output. Existing TCM compositions are mostly designed for human heart failure, failing to fully consider the physiological characteristics of pets (such as metabolic rate and organ function), resulting in limited specificity, limited therapeutic effects, and a lack of clear animal trials to verify their effectiveness and safety.

[0005] Therefore, developing a traditional Chinese medicine composition specifically for heart failure and insufficient cardiac function in pets, with a scientifically formulated composition, definite efficacy, few toxic side effects, and suitability to the physiological characteristics of pets, has significant clinical significance and application value. Summary of the Invention

[0006] In view of the shortcomings of existing drugs for treating heart failure in pets, this invention provides a traditional Chinese medicine composition for treating heart failure and insufficient cardiac function in pets. This composition has a reasonable formula and accurate diagnosis, and can specifically improve symptoms such as insufficient cardiac output and weak myocardial contraction in pets. It has a definite curative effect, few toxic side effects, and is suitable for the physiological and metabolic characteristics of pets.

[0007] To achieve the above objectives, this invention provides a traditional Chinese medicine composition for treating heart failure and insufficient cardiac function. Based on a pet weighing 30 kg, the composition and weight of the raw materials are as follows: ginseng 5-7 g, astragalus 18-22 g, salvia miltiorrhiza 8-12 g, lepidium seed 4-6 g, aconite root 1-3 g, alisma plantago-aquatica 8-12 g, poria cocos 8-12 g, polygonatum odoratum 4-6 g, cinnamon twig 2-4 g, chuanxiong rhizome 1-3 g, coptis chinensis root 1-3 g, and licorice root 2-4 g.

[0008] Preferably, based on a pet weighing 30 kg, the raw materials and weights of the traditional Chinese medicine composition are as follows: 6 g ginseng, 20 g astragalus, 10 g salvia miltiorrhiza, 5 g lepidium seed, 2 g aconite root slices, 10 g alisma rhizome, 10 g poria cocos, 5 g polygonatum odoratum, 3 g cinnamon twig, 2 g chuanxiong rhizome, 2 g coptis rhizome, and 3 g licorice root.

[0009] The composition of this invention follows the traditional Chinese medicine principles of "tonifying qi and warming yang, promoting blood circulation and removing blood stasis, and promoting diuresis and reducing swelling," and combines the pathological characteristics of heart failure and insufficient cardiac function in pets. The ingredients work synergistically to address both the symptoms and the root cause. (1) Ginseng: It can greatly replenish vital energy, restore pulse and consolidate the body. It is the principal medicine. It can replenish heart qi, enhance myocardial contractility, improve insufficient cardiac output, and relieve heart function weakness from the root. It is the core medicine for improving heart qi deficiency in pets.

[0010] (2) Astragalus: It can replenish qi and raise yang, strengthen the exterior and stop sweating, promote diuresis and reduce swelling. As an assistant herb, it can help ginseng to enhance the qi-replenishing effect. At the same time, it can promote diuresis and reduce swelling, alleviate edema symptoms caused by heart failure in pets, improve myocardial metabolism, and protect myocardial cells.

[0011] (3) Danshen: promotes blood circulation, removes blood stasis, relieves pain and menstrual pain; Chuanxiong: promotes blood circulation, removes wind and relieves pain. The two work together to improve myocardial blood circulation, remove blood stasis, relieve myocardial ischemia and hypoxia, and improve cardiac function. They are adjuvant drugs.

[0012] (4) Lepidium seed: clears lung heat and relieves asthma, promotes diuresis and reduces swelling; Alisma rhizome: promotes diuresis and eliminates dampness, clears heat and promotes urination; Poria cocos: promotes diuresis and eliminates dampness, strengthens the spleen and calms the mind. The three work together to clear dampness in the body, reduce the burden on the heart, and relieve symptoms such as difficulty breathing and edema. They are adjuvant drugs.

[0013] (5) Black Shunpian: Restores Yang and rescues from collapse, replenishes fire and assists Yang, dispels cold and relieves pain; Yuzhu: Nourishes Yin and moistens dryness, generates fluids and quenches thirst; Guizhi: Induces sweating and relieves muscle tension, warms and unblocks meridians, assists Yang and transforms Qi. The three work together to warm Yang and nourish Yin, harmonize Qi and blood, improve the state of insufficient heart Yang and deficiency of Yin fluid, and enhance myocardial function. It is an adjuvant medicine.

[0014] (6) Coptis chinensis: It clears heat and dries dampness, drains fire and detoxifies. It can clear internal heat, relieve symptoms such as irritability and internal heat caused by heart failure, and prevent dampness from turning into heat. It is an adjuvant medicine.

[0015] (7) Licorice: It can invigorate qi and replenish the middle jiao, clear heat and detoxify, and harmonize the effects of various medicines. As a medicine, it can moderate the medicinal properties of each medicine and avoid the stimulation of the pet's body by the strong medicine. At the same time, it can enhance the overall qi-replenishing effect, harmonize qi and blood, and water and dampness, so that each medicine can work together.

[0016] The combination of medicinal materials is scientific, with clear distinctions between principal, assistant, adjuvant, and guide herbs. It can replenish heart qi, warm and invigorate heart yang, enhance myocardial contractility, and improve insufficient cardiac output. It can also promote blood circulation, remove blood stasis, promote diuresis and reduce swelling, and reduce the burden on the heart. At the same time, it can nourish yin and clear heat, and regulate bodily functions. It can specifically solve the core pathological problems of heart failure and insufficient cardiac function in pets. Moreover, the medicinal properties are mild and suitable for the physiological characteristics of pets.

[0017] The preparation method of the traditional Chinese medicine composition of the present invention includes the following steps: S1. Raw material screening and processing: Select high-quality Chinese medicinal materials, remove impurities and moldy parts, clean them, dry them and then pulverize them into 80-100 mesh powder for later use; among them, black aconite slices need to be processed in advance to reduce toxicity and ensure safe use.

[0018] S2. Mixing: Mix the raw material powders after the above treatment in proportion to obtain a mixed powder.

[0019] S3. Extraction: Add 8-10 times the weight of distilled water to the mixed powder, soak for 30-60 minutes, then boil and maintain a gentle boil for 30-40 minutes. Filter and collect the filtrate. Add 6-8 times the weight of distilled water to the residue, boil and then maintain a gentle boil for 20-30 minutes. Filter and collect the second filtrate. Combine the two filtrates to obtain the extract.

[0020] S4. Concentration and Drying: The extract is placed in a vacuum concentration tank and concentrated to a thick paste with a relative density of 1.10-1.20 at 60-70℃ and a vacuum degree of 0.06-0.08MPa. Then, it is dried by spray drying at an inlet air temperature of 180-200℃ and an outlet air temperature of 80-100℃ to obtain a dry powder.

[0021] S5. Formulation: Add an appropriate amount of pet-acceptable excipients (such as starch, lactose, steviol glycosides, etc.) to the dried powder, mix well, and make into granules, powders or tablets for easy administration to pets.

[0022] The above preparation method is simple and convenient to operate. It can effectively extract the effective components of various Chinese medicinal materials, retain their efficacy, reduce the toxicity of black aconite, ensure the safety and effectiveness of the composition, and the formulation is suitable for pets' consumption habits, which is convenient for clinical promotion and application.

[0023] The method of using the herbal composition of this invention is as follows: Based on a pet weighing 30 kg, take one dose daily, divided into two administrations, dissolved in warm water or mixed into the feed; adjust the dosage according to the pet's weight, increasing or decreasing the dosage by 1 / 6 for every 5 kg increase or decrease in weight; one course of treatment is 7-14 days, and depending on the severity of the pet's condition, one to three courses of treatment can be administered consecutively.

[0024] Therefore, the traditional Chinese medicine composition for treating heart failure and insufficient cardiac function of the present invention has the following beneficial effects: (1) Scientific formulation and accurate diagnosis: The composition of this invention is based on the TCM principle of "tonifying qi and warming yang, promoting blood circulation and removing blood stasis, and promoting diuresis and reducing swelling". Combined with the pathological characteristics of heart failure and insufficient cardiac function in pets, 12 Chinese medicinal materials are carefully selected and matched. The principal, assistant, adjuvant and guide herbs are clearly distinguished. Each herb works synergistically to not only replenish heart qi and enhance myocardial contractility and improve insufficient cardiac output, but also promote blood circulation and remove blood stasis, promote diuresis and reduce swelling, and reduce the burden on the heart. It addresses both the symptoms and the root cause and is highly targeted.

[0025] (2) Definite efficacy and high safety: Through rigorous animal experiments, the traditional Chinese medicine composition of this invention has a significant therapeutic effect on heart failure and insufficient cardiac function in pets. The efficacy of high dose is comparable to that of the positive control drug for pets, and there are no obvious toxic side effects. It does not damage the liver and kidney function of pets, is not easy to develop drug resistance, and is suitable for long-term use. It solves the problem of large toxic side effects and easy drug resistance in the treatment of heart failure in pets by Western medicine.

[0026] (3) Adapted to the physiological characteristics of pets: The dosage of the composition of the present invention is designed based on a pet weighing 30 kg. It can be flexibly adjusted according to the pet's weight. The formulation (granules, powders, tablets) is adapted to the pet's taking habits. The preparation process is simple, convenient to operate, and low in cost, making it easy to promote and apply in clinical practice.

[0027] (4) Filling the technological gap: Most existing Chinese medicine compositions are designed for human heart failure and do not fully consider the physiological characteristics of pets. This invention is specifically developed for pet heart failure and insufficient cardiac function, filling the technological gap of pet-specific Chinese medicine for treating heart failure and providing a new option for the treatment of pet heart failure.

[0028] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0029] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0030] Figure 1The results of serum biochemical markers in each group of dogs were obtained 2 weeks after the experiment. Detailed Implementation

[0031] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.

[0032] To make the objectives, technical solutions, and advantages of this application clearer, more thorough, and more complete, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings and embodiments. The following detailed descriptions are all illustrations of embodiments, intended to provide further detailed explanation of the present invention. Unless otherwise specified, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0033] The instruments, equipment, reagents, and materials used in the examples were all obtained commercially.

[0034] Example 1 A traditional Chinese medicine composition for treating heart failure and insufficient cardiac function in pets, based on a pet weighing 30 kg, consists of the following ingredients and weights: 6 g ginseng, 20 g astragalus, 10 g salvia miltiorrhiza, 5 g lepidium seed, 2 g aconite root, 10 g alisma plantago-aquatica, 10 g poria cocos, 5 g polygonatum odoratum, 3 g cinnamon twig, 2 g chuanxiong rhizome, 2 g coptis chinensis, and 3 g licorice root.

[0035] The preparation method includes the following steps: S1. Raw material screening and processing: Select high-quality ginseng, astragalus, salvia miltiorrhiza, lepidium seed, processed aconite root, alisma plantago-aquatica, poria cocos, polygonatum odoratum, cinnamon twig, chuanxiong rhizome, coptis chinensis, and licorice. Remove impurities and moldy parts, clean them, dry them, and then grind them into 100-mesh powder for later use.

[0036] S2. Mixing: Mix the above raw material powders evenly according to the proportion to obtain a mixed powder.

[0037] S3. Extraction: Add 9 times the weight of distilled water to the mixed powder, soak for 45 minutes, boil and then keep simmering for 35 minutes, filter and collect the filtrate; add 7 times the weight of distilled water to the residue, boil and then keep simmering for 25 minutes, filter and collect the second filtrate; combine the two filtrates to obtain the extract.

[0038] S4. Concentration and Drying: The extract is placed in a vacuum concentration tank and concentrated to a thick paste with a relative density of 1.15 at 65°C and a vacuum degree of 0.07MPa. The paste is then dried using a spray drying method at an inlet air temperature of 190°C and an outlet air temperature of 90°C to obtain a dry powder.

[0039] S5. Preparation: Add an appropriate amount of starch and steviol glycosides to the dry powder, mix evenly, make into granules, each bag contains 20 grams of raw herb, package, and the product is ready.

[0040] Instructions for use: For pets weighing 30 kg, take one packet daily, divided into two doses, dissolved in warm water or mixed into their feed. One course of treatment is 7 days, and two consecutive courses of treatment should be administered.

[0041] Example 2 A traditional Chinese medicine composition for treating heart failure and insufficient cardiac function in pets, based on a pet weighing 30 kg, consists of the following ingredients and weights: 5 g ginseng, 18 g astragalus, 8 g salvia miltiorrhiza, 4 g lepidium seed, 1 g prepared aconite root, 8 g alisma plantago-aquatica, 8 g poria cocos, 4 g polygonatum odoratum, 2 g cinnamon twig, 1 g chuanxiong rhizome, 1 g coptis chinensis, and 2 g licorice root.

[0042] The preparation method includes the following steps: S1. Raw material screening and processing: Select high-quality Chinese medicinal materials, remove impurities and moldy parts, clean them, dry them and then pulverize them into 80-mesh powder for later use; black aconite slices are used after processing.

[0043] S2. Mixing: Mix the above raw material powders evenly according to the proportion to obtain a mixed powder.

[0044] S3. Extraction: Add 8 times the weight of distilled water to the mixed powder, soak for 30 minutes, boil and then keep simmering for 30 minutes, filter and collect the filtrate; add 6 times the weight of distilled water to the residue, boil and then keep simmering for 20 minutes, filter and collect the second filtrate; combine the two filtrates to obtain the extract.

[0045] S4. Concentration and Drying: The extract is placed in a vacuum concentration tank and concentrated to a thick paste with a relative density of 1.10 at 60°C and a vacuum degree of 0.06MPa. The paste is then dried using a spray drying method at an inlet air temperature of 180°C and an outlet air temperature of 80°C to obtain a dry powder.

[0046] S5. Preparation: Add an appropriate amount of lactose to the dry powder, mix well, and make into a powder. Each powder contains 15 grams of raw medicinal material. Package the powder to obtain the final product.

[0047] Instructions for use: For pets weighing 30 kg, take one packet daily, divided into two doses, dissolved in warm water or mixed into their feed. One course of treatment is 10 days, and two consecutive courses of treatment should be administered.

[0048] Example 3 A traditional Chinese medicine composition for treating heart failure and insufficient cardiac function in pets, based on a pet weighing 30 kg, consists of the following ingredients and weights: 7 g ginseng, 22 g astragalus, 12 g salvia miltiorrhiza, 6 g lepidium seed, 3 g aconite root, 12 g alisma plantago-aquatica, 12 g poria cocos, 6 g polygonatum odoratum, 4 g cinnamon twig, 3 g chuanxiong rhizome, 3 g coptis chinensis, and 4 g licorice root.

[0049] The preparation method includes the following steps: S1. Raw material screening and processing: Select high-quality Chinese medicinal materials, remove impurities and moldy parts, clean them, dry them and then pulverize them into 90-mesh powder for later use; black aconite slices are used after processing.

[0050] S2. Mixing: Mix the above raw material powders evenly according to the proportion to obtain a mixed powder.

[0051] S3. Extraction: Add 10 times the weight of distilled water to the mixed powder, soak for 60 minutes, boil and then keep simmering for 40 minutes, filter and collect the filtrate; add 8 times the weight of distilled water to the residue, boil and then keep simmering for 30 minutes, filter and collect the second filtrate; combine the two filtrates to obtain the extract.

[0052] S4. Concentration and Drying: The extract is placed in a vacuum concentration tank and concentrated to a thick paste with a relative density of 1.20 at 70°C and a vacuum degree of 0.08MPa. The paste is then dried using a spray drying method at an inlet air temperature of 200°C and an outlet air temperature of 100°C to obtain a dry powder.

[0053] S5. Preparation: Add an appropriate amount of starch and magnesium stearate to the dry powder, mix evenly, compress into tablets, each tablet containing 2 grams of raw drug, package, and the product is ready.

[0054] Instructions for use: For a pet weighing 30 kg, take 10 tablets daily, divided into 2 doses, with warm water or mixed into the food. One course of treatment is 14 days, and one course of treatment should be taken consecutively.

[0055] Test Example 1 All animal procedures in this experiment strictly followed the "Guidelines for the Ethical Review of Laboratory Animals" and were approved by the Animal Ethics Committee. Animal suffering was minimized during the experiment, and the animals were humanely disposed of after the experiment, which complied with animal ethics requirements and did not involve any procedures that violated animal welfare.

[0056] Experimental animals: Forty healthy adult Beagles, weighing 28-32 kg (average 30 kg), half male and half female, aged 2-5 years, were selected. Clinical examination, electrocardiogram and echocardiogram confirmed normal cardiac function and no cardiovascular disease, abnormal liver and kidney function or other chronic diseases. The breeding environment was uniform, with a temperature of 20-25℃ and humidity of 50-60%. They had free access to water and food and were allowed to acclimatize for 1 week before the experiment began.

[0057] Test drugs: the traditional Chinese medicine composition (granules, each bag containing 20 grams of raw herbs) prepared in Example 1 of this invention; positive control drug: pimoxendan tablets (pet-specific heart failure treatment drug, specification: 2.5 mg / tablet); physiological saline (0.9% sodium chloride injection).

[0058] (1) Construction of heart failure model: A canine heart failure model was established using intraperitoneal injection of doxorubicin: 40 beagle dogs were randomly divided into a blank control group (10 dogs) and a model group (30 dogs). Each dog in the model group was injected intraperitoneally with doxorubicin 2.5 mg / kg once a week for 4 weeks. The blank control group was injected intraperitoneally with an equal volume of physiological saline once a week for 4 weeks.

[0059] After the model was constructed, all dogs underwent echocardiography to measure left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and cardiac output (CO), while clinical symptoms were observed. When dogs in the model group showed symptoms of heart failure such as lethargy, dyspnea, reduced activity, and edema, and LVEF < 50%, LVFS < 25%, and CO < 2.5 L / min, the model was considered to have been successfully constructed.

[0060] (2) The 30 successfully modeled beagle dogs were randomly divided into 3 groups of 10 each, with half males and half females. There were no significant differences in body weight and cardiac function indicators among the groups. P >0.05), indicating comparability; a blank control group (10 normal dogs) was also set up, with the specific grouping as follows: Blank control group: normal dogs, no model was constructed, no drugs were given, and they were allowed free access to water and food for 2 consecutive weeks.

[0061] Model control group: Heart failure model dogs were given an equal volume of physiological saline once a day for two consecutive weeks by gavage.

[0062] Low-dose group of traditional Chinese medicine composition: Heart failure model dogs were given the traditional Chinese medicine composition of Example 1 of this invention at a dose of 0.5 bags / dog / day (equivalent to 10 grams of raw medicine / dog / day), once a day, for two consecutive weeks by gavage.

[0063] High-dose group of traditional Chinese medicine composition: Heart failure model dogs were given the traditional Chinese medicine composition of Example 1 of the present invention at a dose of 1 bag / dog / day (equivalent to 20 grams of raw medicine / dog / day), once a day, for 2 consecutive weeks by gavage.

[0064] Positive control group: Heart failure model dogs were given pimoxand tablets at a dose of 0.2 mg / kg / day, once a day, for two consecutive weeks by gavage.

[0065] (3) During the experiment, the clinical symptoms (mental state, respiration, activity level, edema, etc.) of each group of dogs were observed and recorded daily; the following indicators were tested on each group of dogs before the start of the experiment (T0), one week after the experiment (T1), and two weeks after the experiment (T2): Cardiac function indicators: Left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and cardiac output (CO) were measured using echocardiography. Each indicator was measured 3 times and the average value was taken.

[0066] Serum biochemical indicators: Venous blood was collected from dogs, and serum was separated by centrifugation. The levels of creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the serum were detected using a blood biochemistry analyzer to reflect myocardial injury and cardiac function status.

[0067] Safety indicators: Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (Cr), and blood urea nitrogen (BUN) levels were measured. The dogs' diet and defecation were observed to determine the effects of the drug on liver and kidney function. After the experiment, some dogs were dissected to observe pathological changes in organs such as the heart, liver, and kidneys.

[0068] (4) Based on the improvement of clinical symptoms and cardiac function indicators, the therapeutic effect is divided into three levels: significant effect, effective, and ineffective. Significant effect: clinical symptoms completely disappear, mental state, respiration and activity level return to normal, edema subsides; LVEF≥55%, LVFSF≥30%, COF≥3.0L / min, serum NT-proBNP, CK, LDH and AST levels return to normal.

[0069] Effective: Clinical symptoms significantly improved, mental state improved, dyspnea reduced, activity level increased, and edema significantly subsided; 50%≤LVEF<55%, 25%≤LVFS<30%, 2.5L / min≤CO<3.0L / min, serum NT-proBNP, CK, LDH, and AST levels decreased by ≥30% compared to before treatment.

[0070] Ineffective: No improvement or even worsening of clinical symptoms, no significant change or decrease of <30% in cardiac function indicators, and no improvement in serum biochemical indicators.

[0071] Overall effectiveness = (number of cases with significant effect + number of cases with effect) / total number of cases × 100%.

[0072] (5) Experimental results: ① Improvement of clinical symptoms: During the experiment, the dogs in the blank control group were in good spirits, had stable breathing, normal activity, and no abnormal symptoms; the dogs in the model control group were lethargic, had difficulty breathing, and significantly reduced activity, and some dogs developed edema in their limbs, and the symptoms gradually worsened; the clinical symptoms of the dogs in the low-dose group, high-dose group and positive control group of the Chinese medicine composition gradually improved, with the high-dose group showing the most significant improvement. After 2 weeks of the experiment, most dogs' spirits returned to normal, breathing became stable, activity increased, and edema subsided.

[0073] ②The results of the snack function indicators of each group of dogs at different time points are shown in Table 1 below.

[0074] Table 1 Results of cardiac function index tests

[0075] Note: Compared with the model control group, Compared with the low-dose group of traditional Chinese medicine, # P <0.05.

[0076] As shown in Table 1, before the experiment (T0), the cardiac function indicators (LVEF, LVFS, CO) of the model control group, the low-dose traditional Chinese medicine group, the high-dose traditional Chinese medicine group, and the positive control group were all significantly lower than those of the blank control group. P <0.05, no significant difference between groups ( P >0.05); Two weeks after the experiment (T2), there were no significant changes in cardiac function indicators in the model control group ( P >0.05), cardiac function indicators were significantly increased in the low-dose traditional Chinese medicine group, the high-dose traditional Chinese medicine group, and the positive control group. P <0.05, with no significant difference between the high-dose traditional Chinese medicine group and the positive control group ( P <0.05, and significantly higher than the low-dose traditional Chinese medicine group ( P <0.05), indicating that the herbal composition of the present invention can significantly improve cardiac contractile function and increase cardiac output in heart failure model dogs, and the effect is better at higher doses, comparable to the efficacy of the positive control drug.

[0077] ③ The serum biochemical indicators of each group of dogs after 2 weeks of testing are as follows: Figure 1 As shown in Table 2 below.

[0078] Table 2 Results of serum biochemical markers

[0079] Note: Compared with the model control group, Compared with the low-dose group of traditional Chinese medicine, # P <0.05.

[0080] As shown in Table 2, after 2 weeks of the experiment, the serum levels of CK, LDH, AST, and NT-proBNP in the model control group were significantly higher than those in the blank control group. P <0.05 indicates that the model dogs have significant myocardial damage and severe cardiac insufficiency; the serum CK, LDH, AST, and NT-proBNP levels in the low-dose traditional Chinese medicine group, high-dose traditional Chinese medicine group, and positive control group were significantly lower than those in the model control group. P <0.05, with no significant difference between the high-dose traditional Chinese medicine group and the positive control group ( P >0.05%, and significantly lower than the low-dose traditional Chinese medicine group ( P<0.05), indicating that the herbal composition of the present invention can significantly reduce myocardial damage in heart failure model dogs, reduce serum NT-proBNP levels, and improve cardiac function, with higher doses showing better effects.

[0081] ④ Safety test results.

[0082] During the experiment, no dogs died in any group. The dogs in the blank control group, low-dose traditional Chinese medicine group, high-dose traditional Chinese medicine group, and positive control group all had normal eating and defecating habits and no obvious adverse reactions. After two weeks of the experiment, the serum ALT, AST, Cr, and BUN levels in all groups were within the normal range and showed no significant difference compared to the blank control group. P >0.05); After dissection, no obvious pathological damage was found in the heart, liver, kidneys and other organs of the dogs in each group, indicating that the traditional Chinese medicine composition of the present invention has high safety, no obvious toxic side effects, and no damage to the liver and kidney function of pets.

[0083] ⑤ After 2 weeks of the experiment, the statistical results of the therapeutic effects in each group of dogs are shown in Table 3 below.

[0084] Table 3 Statistical Results of Therapeutic Effect

[0085] Note: Compared with the model control group, Compared with the low-dose group of traditional Chinese medicine, # P <0.05.

[0086] As shown in Table 3, the total effective rate of the model control group was only 10.0%, indicating extremely poor efficacy; the total effective rate of the low-dose traditional Chinese medicine group was 70.0%, significantly higher than that of the model control group. P <0.05); The total effective rate of the high-dose traditional Chinese medicine group and the positive control group was 90.0%, which was significantly higher than that of the model control group and the low-dose traditional Chinese medicine group. P The results showed that the concentration of the herbal medicine composition in the present invention was <0.05%, and there was no significant difference between the two, indicating that the herbal medicine composition of the present invention has a significant therapeutic effect on heart failure and insufficient cardiac function in pets, and the efficacy of high dose is comparable to that of the positive control drug.

[0087] Therefore, this invention provides a traditional Chinese medicine composition for treating heart failure and insufficient cardiac function, which can significantly improve the clinical symptoms of heart failure model dogs, increase left ventricular ejection fraction, left ventricular fractional shortening, and cardiac output, reduce serum CK, LDH, AST, and NT-proBNP levels, alleviate myocardial damage, and improve the state of insufficient cardiac function. It also exhibits high safety, with no obvious toxic side effects and no damage to the liver and kidneys of pets. The high dose (based on a 30 kg pet, one sachet daily, containing 20 grams of raw herbs) shows the best efficacy, comparable to the positive control drug pimoxendan tablets. It can be effectively used to treat heart failure and insufficient cardiac output in pets and has promising clinical application prospects.

[0088] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. A traditional Chinese medicine composition for treating heart failure and insufficient cardiac function, characterized in that, Based on a pet weighing 30 kg, the medication is prepared from the following raw materials in parts by weight: ginseng 5-7 g, astragalus 18-22 g, salvia miltiorrhiza 8-12 g, lepidium seed 4-6 g, aconite root 1-3 g, alisma plantago-aquatica 8-12 g, poria cocos 8-12 g, polygonatum odoratum 4-6 g, cinnamon twig 2-4 g, chuanxiong rhizome 1-3 g, coptis chinensis root 1-3 g, and licorice root 2-4 g.

2. The traditional Chinese medicine composition for treating heart failure and insufficient cardiac function according to claim 1, characterized in that: Based on a pet weighing 30 kg, the medication is prepared from the following raw materials: 6 g ginseng, 20 g astragalus, 10 g salvia miltiorrhiza, 5 g lepidium seed, 2 g aconite root, 10 g alisma rhizome, 10 g poria cocos, 5 g polygonatum odoratum, 3 g cinnamon twig, 2 g chuanxiong rhizome, 2 g coptis rhizome, and 3 g licorice root.

3. The traditional Chinese medicine composition for treating heart failure and insufficient cardiac function according to claim 1, characterized in that: The aforementioned cardiac insufficiency refers to insufficient cardiac output.

4. A method for preparing the traditional Chinese medicine composition according to any one of claims 1-3, characterized in that, Includes the following steps: S1. Clean and pulverize all raw materials; S2. Add water and decoct to extract, filter, and combine the filtrates; S3. Concentrate and dry to obtain the extract; S4. Mix the extract with pharmaceutically acceptable excipients to prepare a pet-safe formulation.

5. The preparation method according to claim 4, characterized in that: The preparation is any one of powder, granule, or tablet.

Images